Economy
Moderna and Merck stocks rally on melanoma vaccine success
Moderna and Merck stock prices surged after Phase 3 trial data showed their combined mRNA vaccine slowed recurrence and metastasis in melanoma patients.
Moderna and Merck stock prices surged after Phase 3 trial data showed their combined mRNA vaccine slowed recurrence and metastasis in melanoma patients.